多柔比星联合奥拉单抗对比多柔比星联合安慰剂对晚期软组织肉瘤生存的影响:ANNOUNCE随机临床试验
ANNOUNCE是一项在25国110个中心开展的3期双盲随机确证性试验,纳入509例蒽环类未治的晚期/转移性软组织肉瘤患者,比较多柔比星联合奥拉单抗与联合安慰剂。结果显示两组总生存无显著差异,未重复2期试验中观察到的生存获益。
要点
- 多柔比星联合奥拉单抗未改善晚期软组织肉瘤患者的总生存。
- 总STS人群HR 1.05(95%CI 0.84-1.30,P=0.69),中位OS 20.4 vs 19.7个月。
核心结论
- 在晚期软组织肉瘤患者中,多柔比星联合奥拉单抗对比联合安慰剂未显著改善总生存。
- 该3期试验结果未确认2期试验中观察到的总生存获益。
研究设计与样本
- 纳入509例蒽环类未治、不可切除局部晚期或转移性STS成人患者,ECOG评分0-1,心脏射血分数≥50%。
- 患者按1:1随机接受多柔比星75 mg/m2联合奥拉单抗(n=258)或安慰剂(n=251)。
- 奥拉单抗第1周期20 mg/kg、后续周期15 mg/kg,第1和8天给药,最多8个21天周期,之后奥拉单抗/安慰剂单药治疗。
- 双主要终点为总STS和LMS人群的总生存。
主要发现
- 总STS人群:多柔比星联合奥拉单抗组对比安慰剂组HR 1.05(95%CI 0.84-1.30,P=0.69),中位OS 20.4个月 vs 19.7个月。
- 总STS患者中发生率≥15%的≥3级不良事件包括中性粒细胞减少(46.3% vs 49.0%)、白细胞减少(23.3% vs 23.7%)和发热性中性粒细胞减少(17.5% vs 16.5%)。
临床怎么用
- 不推荐在晚期软组织肉瘤中常规联合奥拉单抗与多柔比星,因3期试验未显示总生存获益。
- 临床决策应基于3期确证性证据而非2期探索性结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Patients with advanced soft tissue sarcoma (STS) have a median overall survival of less than 2 years. In a phase 2 study, an overall survival benefit in this population was observed with the addition of olaratumab to doxorubicin over doxorubicin alone. OBJECTIVE: To determine the efficacy of doxorubicin plus olaratumab in patients with advanced/metastatic STS. DESIGN, SETTING, AND PARTICIPANTS: ANNOUNCE was a confirmatory, phase 3, double-blind, randomized trial conducted at 110 sites in 25 countries from September 2015 to December 2018; the final date of follow-up was December 5, 2018. Eligible patients were anthracycline-naive adults with unresectable locally advanced or metastatic STS, an Eastern Cooperative Oncology Group performance status of 0 to 1, and cardiac ejection fraction of 50% or greater. INTERVENTIONS: Patients were randomized 1:1 to receive doxorubicin, 75 mg/m2 (day 1), combined with olaratumab (n = 258), 20 mg/kg in cycle 1 and 15 mg/kg in subsequent cycles, or placebo (n = 251) on days 1 and 8 for up to 8 21-day cycles, followed by olaratumab/placebo monotherapy. MAIN OUTCOMES AND MEASURES: Dual primary end points were overall survival with doxorubicin plus olaratumab vs doxorubicin plus placebo in total STS and leiomyosarcoma (LMS) populations. RESULTS: Among the 509 patients randomized (mean age, 56.9 years; 58.2% women; 46.0% with LMS), all were included in the primary analysis and had a median length of follow-up of 31 months. No statistically significant difference in overall survival was observed between the doxorubicin plus olaratumab group vs the doxorubicin plus placebo group in either population (total STS: hazard ratio, 1.05 [95% CI, 0.84-1.30], P = .69, median overall survival, 20.4 months vs 19.7 months; LMS: hazard ratio, 0.95 [95% CI, 0.69-1.31], P = .76, median overall survival, 21.6 months vs 21.9 months). Adverse events of grade 3 or greater reported in 15% or more of total patients with STS were neutropenia (46.3% vs 49.0%), leukopenia (23.3% vs 23.7%), and febrile neutropenia (17.5% vs 16.5%). CONCLUSIONS AND RELEVANCE: In this phase 3 clinical trial of patients with advanced STS, treatment with doxorubicin plus olaratumab vs doxorubicin plus placebo resulted in no significant difference in overall survival. The findings did not confirm the overall survival benefit observed in the phase 2 trial. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02451943.
引用
- Tap WD, Wagner AJ, Schöffski P, et al. Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial. JAMA. 2020. PMID: 32259228. doi:10.1001/jama.2020.1707
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。